2026-05-20T04:01:54Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/235472024-11-28T17:22:41Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16960col_20.500.12105_16967

00925njm 22002777a 4500 dc Bento, Leyre author Canaro Hirnyk, Mariana author Bastida, Jose Maria author Sampol Mayol, Antonia author 2022-03 Thrombocytopenia following allogeneic hematopoietic stem cell transplantation is a usual complication and can lead to high morbidity and mortality. New strategies, such as the use of another graft versus host-disease prophylaxis, alternative donors, and management of infections, have improved the survival of these patients. The mechanisms are unknown; therefore, the identification of new strategies to manage this potentially serious problem is needed. Thrombopoietin receptor agonists are currently available to stimulate platelet production. Some small retrospective studies have reported their potential efficacy in an allogeneic stem cell transplant setting, confirming good tolerability. Recent studies with higher numbers of patients also support their safety and efficacy in this setting, hence establishing the use of these drugs as a promising strategy for this post-transplant complication. However, prospective trials are needed to confirm these results. Bento L, Canaro M, Bastida JM, Sampol A. Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation. J Clin Med. 2022 Mar;11(5):1364. 10.3390/jcm11051364 2077-0383 Journal of Clinical Medicine https://hdl.handle.net/20.500.13003/19876 35268455 L2015794790 2-s2.0-85127627320 https://hdl.handle.net/20.500.12105/23547 769306100001 Allogeneic stem cell transplantation Thrombocytopenia Morbidity Thrombopoietin receptor agonists Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation